Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.

Autor: Grande E; Hospital Ramon y Cajal, Madrid, Spain., Bamias A; National & Kapodistrian University of Athens, Athens, Greece., Galsky MD; Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY, USA., Kikuchi E; Keio University Hospital, Tokyo, Japan., Davis ID; Monash University, Melbourne, Australia.; Eastern Health Clinical School, Melbourne, Australia., Arranz JÁ; Gregorio Maranon Hospital, Madrid, Spain., Rezazadeh Kalebasty A; Norton Cancer Institute, Louisville, KY, USA., Garcia Del Muro X; Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Alekseev B; Research Oncology Institute, Tomsk, Russia., Mencinger M; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Izumi K; Kanazawa University Hospital, Kanazawa, Japan., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, CIBERONC, Madrid, Spain., Li JR; Taichung Veterans General Hospital, Taichung, Taiwan., Bernhard S; Roche Products Limited, Welwyn Garden City, UK., Nicholas A; Genentech Inc., South San Francisco, CA, USA., Telliez J; F. Hoffmann-La Roche Ltd., Basel, Switzerland., De Santis M; Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.; Department of Urology, Medical University Vienna, Vienna, Austria.

Publikováno v: European urology open science [Eur Urol Open Sci] 2023 Nov 04; Vol. 58, pp. 28-36. Date of Electronic Publication: 2023 Nov 04 (Print Publication: 2023).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

JAK inhibitor selectivity: new opportunities, better drugs?

Autor: Virtanen A; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Spinelli FR; Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza Universitá di Roma, Rome, Italy., Telliez JB; Inflammation and Immunology, Pfizer, Cambridge, MA, USA., O'Shea JJ; Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA., Silvennoinen O; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Fimlab laboratories, Tampere, Finland., Gadina M; Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. gadinama@nih.gov.

Publikováno v: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2024 Oct; Vol. 20 (10), pp. 649-665. Date of Electronic Publication: 2024 Sep 09.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.

Autor: Farnos, Camille¹ (AUTHOR) farnos.camille@chu-amiens.fr, Barbier, Vincent² (AUTHOR), Doussiere, Marie¹ (AUTHOR), Deprez, Valentine¹ (AUTHOR), Hamidou, Yannis¹ (AUTHOR), Bruy, Pierre Antoine¹ (AUTHOR), Sobhy Danial, Jean Marc¹ (AUTHOR), Goeb, Vincent¹ (AUTHOR)

Publikováno v: Journal of Clinical Medicine. Aug2024, Vol. 13 Issue 16, p4608. 13p.